Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hong-Hong Yan

Showing results (61-70 of 118) with videos related to

Pageof 12
Sort By:
Clinical Lung Cancer|December 15, 2020
Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)Xiang-Meng Li, Wen-Feng Li, Jun-Tao Lin, et al.
Journal for Immunotherapy of Cancer|July 2, 2020
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort studyXue Bai, De-Hua Wu, Si-Cong Ma, et al.
World Journal of Surgical Oncology|January 11, 2017
Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective studySong Dong, Ning Zhao, Wei Deng, et al.
The Oncologist|June 8, 2012
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomasZhi-Yong Chen, Wen-Zhao Zhong, Xu-Chao Zhang, et al.
Science Bulletin|January 20, 2023
The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challengeYi-Chen Zhang, Qing Zhou, Zhi-Hong Chen, et al.
The Lancet. Respiratory Medicine|July 24, 2017
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trialJin-Ji Yang, Caicun Zhou, Yisheng Huang, et al.
BMC Cancer|November 28, 2018
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpressionRui-Lian Chen, Jun Zhao, Xu-Chao Zhang, et al.
Ebiomedicine|September 14, 2020
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinomaHao Sun, Si-Yang Liu, Jia-Ying Zhou, et al.
Therapeutic Advances in Medical Oncology|April 28, 2023
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patientsZhen Wang, Xu-Chao Zhang, Wei-Neng Feng, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastasesKai Yin, Yang-Si Li, Mei-Mei Zheng, et al.
Pageof 12

Showing results (61-70 of 118) with videos related to

Sort By:
Pageof 12
Clinical Lung Cancer|December 15, 2020
Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)Xiang-Meng Li, Wen-Feng Li, Jun-Tao Lin, et al.
Journal for Immunotherapy of Cancer|July 2, 2020
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort studyXue Bai, De-Hua Wu, Si-Cong Ma, et al.
World Journal of Surgical Oncology|January 11, 2017
Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective studySong Dong, Ning Zhao, Wei Deng, et al.
The Oncologist|June 8, 2012
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomasZhi-Yong Chen, Wen-Zhao Zhong, Xu-Chao Zhang, et al.
Science Bulletin|January 20, 2023
The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challengeYi-Chen Zhang, Qing Zhou, Zhi-Hong Chen, et al.
The Lancet. Respiratory Medicine|July 24, 2017
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trialJin-Ji Yang, Caicun Zhou, Yisheng Huang, et al.
BMC Cancer|November 28, 2018
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpressionRui-Lian Chen, Jun Zhao, Xu-Chao Zhang, et al.
Ebiomedicine|September 14, 2020
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinomaHao Sun, Si-Yang Liu, Jia-Ying Zhou, et al.
Therapeutic Advances in Medical Oncology|April 28, 2023
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patientsZhen Wang, Xu-Chao Zhang, Wei-Neng Feng, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastasesKai Yin, Yang-Si Li, Mei-Mei Zheng, et al.
Pageof 12